Sarcomas | Specialty

The sarcomas/tgct condition center is a comprehensive resource for clinical news and expert insights on sarcomas/tgct. Read more at OncLive.

Optimal Timing for Introducing Afami-Cel Therapy in the Treatment Journey

January 21st 2025

A panelist discusses how afamitresgene autoleucel (afami-cel) therapy should be considered early in the treatment journey after initial standard of care when patients still have good performance status and adequate organ function to maximize the potential benefit of this cellular therapy approach.

Key Differences in T-Cell Response Therapy vs CAR T Therapy

January 21st 2025

A panelist discusses how T-cell receptor (TCR) therapy offers potential advantages over chimeric antigen receptor (CAR) T therapy in solid tumors due to its ability to recognize intracellular antigens through human leukocyte antigen (HLA) presentation and its generally better safety profile with lower cytokine release syndrome rates, though TCR therapy faces its own challenges, including HLA restriction and potential cross-reactivity risks.

Dr Mowery on Pembrolizumab Plus Radiation Therapy and Surgery in Soft Tissue Sarcoma

January 20th 2025

Yvonne Mowery, MD, PhD, discusses the SU2C-SARC032 trial of pembrolizumab plus radiotherapy followed by surgery in soft tissue sarcoma.

Pembrolizumab/Radiation/Surgery Improves DFS in Stage III Soft Tissue Sarcoma

January 18th 2025

The addition of pembrolizumab to preoperative radiation therapy followed by surgery prolonged DFS in patients with soft tissue sarcoma of the extremity.

Early Diagnosis and Treatment Are Critical in Achieving the Best Outcomes in Sarcoma

January 16th 2025

Breelyn Wilky, MD, discusses the importance of disease screening and early diagnosis in the treatment of patients with sarcoma.

Lete-Cel Receives FDA Breakthrough Therapy Designation for Advanced Myxoid/Round Cell Liposarcoma

January 16th 2025

The FDA granted breakthrough therapy designation to lete-cel for patients with unresectable or metastatic myxoid/round cell liposarcoma.

OST-HER2 Meets Primary End Point of Phase 2b Trial in Lung-Only Metastatic Osteosarcoma

January 16th 2025

OST-HER2 shows promise in patients with recurrent, fully resected lung-only metastatic osteosarcoma.

Afami-cel Approval and Its Potential Influence on the Adoption of TCR Therapies

January 14th 2025

Panelists discuss how the approval of afamitresgene autoleucel (afami-cel) as the first T-cell receptor (TCR) therapy marks a pivotal milestone that could accelerate development and acceptance of TCR-based treatments by establishing regulatory precedent, validating the therapeutic approach, and providing real-world evidence of safety and efficacy in solid tumors.

GSK’227 Earns FDA Breakthrough Therapy Designation for Late-Line R/R Osteosarcoma

January 10th 2025

The FDA has granted breakthrough therapy designation to GSK5764227 for the treatment of relapsed/refractory osteosarcoma.

SPEARHEAD-1: Overview of Study Design, Key Efficacy, and Safety

January 7th 2025

Panelists discuss how afamitresgene autoleucel (afami-cel) demonstrated meaningful clinical activity in SPEARHEAD-1, with manageable cytokine release syndrome as the main safety concern.

Addressing Unmet Needs in Synovial Sarcoma and Recent FDA Approval of Afami-cel

January 3rd 2025

Panelists discuss how the major unmet needs in treating synovial sarcoma include developing targeted therapies that effectively address the SS18::SSX fusion oncogene, improving early detection methods, and finding ways to overcome treatment resistance in metastatic disease.

Brief Overview of Synovial Sarcoma: What It Is, Clinical Presentation and Diagnosis

December 24th 2024

Panelists discuss how synovial sarcoma is a rare soft-tissue cancer characterized by its unique SS18::SSX fusion oncogene transcript, which distinguishes it from other sarcomas and drives its aggressive behavior through altered epigenetic regulation, despite its misleading name suggesting origin in synovial tissue.

Osteosarcoma Spheroid Models Provide Key Tool for Preclinical Drug Development

December 23rd 2024

R. Lor Randall, MD, FACS, discusses the construction and preclinical utility of spheroid models for drug development in osteosarcoma.

Translating Metabolic Therapies Into Sarcoma

December 18th 2024

Brian A. Van Tine, MD, PhD, of Washington University of St. Louis and Siteman Cancer Center, discusses how to translate metabolic therapies into sarcoma management.

Dr D'Angelo on the Significance of Lete-Cel Treatment Across Sarcoma Subtypes

December 17th 2024

Sandra P. D’Angelo, MD, discusses data from substudy 2 of the phase 2 IGNYTE-ESO trial evaluating lete-cel in SyS and MRCLS.

Preclinical Data Highlight YAP1 and KRAS as Drivers in Soft Tissue Sarcomas

December 5th 2024

R. Lor Randall, MD, FACS, discusses advancements in preclinical research identifying therapeutic vulnerabilities in soft tissue sarcomas.

FDA Approves Oral Solution of Imatinib for Certain Leukemias, Other Cancers

November 25th 2024

The FDA has approved an oral solution of imatinib for the treatment of certain leukemias and other cancers.

Elraglusib Earns FDA Rare Pediatric Disease Designation for Ewing Sarcoma

November 12th 2024

The FDA has awarded rare pediatric disease designation to the novel GSK-3β inhibitor elraglusib for the treatment of Ewing sarcoma.

Pimicotinib Meets ORR End Point in Tenosynovial Giant Cell Tumor

November 12th 2024

Pimicotinib improved responses compared with placebo in tenosynovial giant cell tumor.

Fixed-Dose CAR T Cells Followed by Escalating UB-TT170 Increases Cytokine Levels in R/R Osteosarcoma

November 11th 2024

Administration of fixed-dose CAR T cells followed by escalating doses of UB-TT170 led to changes in cytokine levels in relapsed/refractory osteosarcoma.